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Abstract
2-Methoxyestradiol (2-ME) has potent antiproliferative
effects on cancer cells. Its utility alone or in combina-
tion with other therapies for treating prostate cancer,
however, has not been fully explored. Androgen-
dependent and independent human prostate cancer
cells were examined in vivo for their response to com-
bination therapy. Efficacy was assessed by terminal
deoxynucleotide transferase–mediated dUTP nick-end
labeling assay and measuring microvessel density
(MVD) in excised tumors. Animals harboring hormone-
dependent tumors treated with 2-ME alone, androgen
deprivation therapy alone, or the combination of the
two had a 3.1-fold, 5.3-fold, and 10.1-fold increase in
apoptosis, respectively. For hormone-independent
tumors, treatment with 2-ME resulted in a 2.43-fold in-
crease in apoptosis and a 73% decrease in MVD. 2-ME
was most effective against hormone-dependent
tumors in vivo and combination therapy resulted in a
significant increase in efficacy compared to no treat-
ment controls and trended toward greater efficacy than
either 2-ME or androgen deprivation alone. Combina-
tion therapy should be investigated further as an ad-
ditional therapeutic option for early prostate cancer.
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Introduction
Cell growth and cell death are highly regulated ongoing
cellular processes, the ratio of which is responsible for tis-
sue renewal and homeostasis within an organism. In gen-
eral, cancer results as a perturbation of this tightly regulated
ratio such that cellular growth exceeds death. Therefore,
modulation of the ratio by decreasing cell growth, increasing
cell death, or both, can stop cancer. For prostate cancer,
androgens are the major perturbants of this balance, both
stimulating proliferation and inhibiting apoptosis through
the androgen receptor. Because removal of hormones both
inhibits proliferation and increases apoptosis of prostate
cancer, androgen deprivation therapy has been the gold stan-
dard for the past 30 years in patients with advanced pros-
tate cancer [1]. Although initially effective at blocking tumor
growth, androgen deprivation therapy eventually fails, leading
to a uniformly lethal drug-resistant stage of the cancer, called
androgen-independent disease [2]. There is some divergence
in thought if the hormone-independent form of the disease is
selected by hormone deprivation therapy, or is the result of
a new mutation. It is clear, however, that a large number of
cancers originally classified as androgen-dependent prostate
cancer (ADPC) have the ability to change status from androgen-
dependent to androgen-independent growth, which is far more
difficult to manage [2]. Thus, in the longer term, androgen dep-
rivation therapy is not an effective first-line treatment for pros-
tate cancer, and there exists a need to develop better therapeutic
modalities for early-stage prostate cancer.
2-Methoxyestradiol (2-ME) is an endogenous metabolite of
17-b-estradiol reported to have high antiangiogenic activity [3]
and to directly inhibit the growth of various cancer cells in vitro
[3,4,5] as well as solid tumors in vivo, such as melanoma [6],
breast cancer [7], and prostate cancer [7,8]. Both anti-
angiogenic and antitumor actions of 2-ME suggest that it may
well have a tremendous potential for fighting cancer [9,10]
and as a first-line therapy for ADPC. Despite these results,
neither clinical nor animal trials with this agent have addressed
hormone-dependent prostate disease. A recent report sug-
gests that the antitumor action of this molecule is not depen-
dent on the a or b estrogen receptor [11], but that 2-ME may
induce apoptosis in cancer cells through a variety of molecular
targets including c-Jun N-terminal kinase (JNK) [8,10,12,13].
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Because 2-ME has minimal estrogenic effects, it is expected
to have little, if any, of the cardiotoxicity associated with es-
trogen [14]. In a recent clinical trial of 2-ME for advanced
prostate cancer, efficacy was shown without serious adverse
effects and little significant toxicity was noted with doses
exceeding 1000 mg/body per day [7]. Clinical trials are now
underway to test this agent against nontreated locally ad-
vanced prostate cancer and against metastatic androgen-
independent prostate cancer (AIPC).
One of the important questions not addressed in these
trials, however, is if 2-ME, alone or in combination with an-
drogen deprivation therapy, is an effective treatment for
ADPC, thereby potentially impacting the later development
of hormone-independent cancer. It seems likely that an early
combinatorial approach with these agents for ADPC might
have increased efficacy because 2-ME and androgen depri-
vation therapy act on different molecular targets within both
the tumor and the vasculature.
Although the antiproliferative and apoptotic effects of
2-ME on human prostate cancer cells have been demon-
strated, most of these studies have looked at later time
points and prolonged treatment periods. In the work pre-
sented here, we have studied the early effects of this treat-
ment on both ADPC and AIPC. We report here that 2-ME
treatment induced apoptosis both of ADPC and AIPC, as
well as decreased tumor microvessel density (MVD) in vivo.
In addition, the combination of 2-ME treatment and an-
drogen deprivation therapy showed an increased efficacy
in stimulating apoptosis and decreasing MVD in ADPC.
Further long-term studies will be required to address if
combination therapy will impact the conversion of ADPC to
hormone-independent cancer.
Materials and Methods
Tumor Models
The HONDA xenograft tumor model was originally de-
rived from a metastatic human prostate carcinoma and was
kindly provided by Dr. Y. Ito (Gunma University, Maebashi
City, Gunma, Japan). The HONDA tumor model has been
characterized as an androgen-dependent and prostate-
specific antigen (PSA) producing prostate cancer [15,16],
and the xenografts undergo rapid tumor regression after
castration of the mouse host. HONDA tumors were main-
tained in vivo by serial passage in nu/nu mice. For experi-
ments, tumors were resected using sterile technique from
the flanks of nu/nu mice and minced into 2-mm cubes in
serum-free RPMI 1640 medium on ice. Individual tumor
cubes were transplanted subcutaneously into the flank of
the male nu/nu mice that had been implanted with a 12.5-mg
testosterone pellet (Innovative Research of America, Sara-
sota, FL) 2 days earlier. Supplemental testosterone was
used for all studies to normalize the level of circulating an-
drogens and to increase tumor take rates [17,18].
PC-3 cells were obtained from the American Type Culture
Collection (Manassas, VA) and were used as a model of
AIPC. One million PC-3 cells were resuspended in Matrigel
(Becton Dickinson, Bedford, MA) diluted 1:1, and subcuta-
neously injected to nu/nu mice. PC-3 tumor-bearing mice did
not receive testosterone pellets. The mice were housed
under standard conditions with food and water ad libitum.
Three to 4 weeks after tumor implantation, when the tumor
volumes were approximately 600 mm3 (HONDA) and
300 (PC-3) mm3, the mice were allocated into different treat-
ment groups with visual sorting to standardize the average
size of tumors within groups.
Mice were grouped as outlined in Figure 1. For HONDA
tumors: group 1 was injected with vehicle, 0.2 ml of sterile
olive oil (Sigma Chemical, St. Louis, MO), given intra-
peritoneally daily; group 2 was injected with 2-ME (Sigma
Chemical), 20 mg/kg per day, approximately 0.2 ml given
intraperitoneally daily; group 3 received androgen depri-
vation therapy (androgen pellet removal plus surgical cas-
tration); and group 4 received combined therapy, 2-ME
treatment and androgen deprivation, as described above.
The daily dose of 2-ME was based on a previous report
showing that 1000 mg/body per day was well tolerated in
prostate and breast cancer patients [7]. Groups 1 and 2 re-
ceived sham surgeries to control for surgical effects on tumor
growth and vascularization. In the experiments demon-
strated in Figures 3–6, the mean tumor sizes were 642 mm3
onday0and1589mm3onday3 in control animals; 641 mm3 on
day 0 and 962 on day 3 in 2-ME–treated animals; 650 mm3
on day 0 and 619 mm3 on day 3 in castrated animals; and
681 mm3 on day 0 and 465 mm3 on day 3 in animals treated
with combination therapy.
For studies with PC-3 tumors, only groups 1 and 2 were
investigated. For PC-3 human prostate cancer: group 1 was
injected with vehicle and group 2 was injected with 2-ME
(20 mg/kg per day, approximate total volume of 0.2 ml). For
both series of experiments, 2-ME was prepared by dis-
solving and sonicating it in sterile olive oil at a concentration
of 2 mg/ml. Seventy-two hours after initial treatment, all
animals were euthanized for analysis. Tumor size was mea-
sured by microcalipers and the tumor volume was calcu-
lated as reported previously [19]. All animal experiments were
done with the permission of the local ethical committee.
For all studies, no androgen receptor blockade was
utilized.
Immunohistochemistry and Terminal Deoxynucleotide
Transferase–Mediated dUTP Nick-End Labeling
(TUNEL) Assay
Tumors excised from euthanized animals were fixed with
4% paraformaldehyde for 24 to 48 hours at 4jC, and then
washed in 0.1 M phosphate-buffered saline (PBS; pH 7.4).
The tissues were snap-frozen in TissueTek embedding
medium (Sakura, Zoeterwoude, The Netherlands) and cut
into 7-mm sections using a CM 1900 Cryotome (Leica Micro-
systems, Wetzlar, Germany). To reveal the presence of
androgen receptor or PSA in HONDA tumors, a rabbit anti-
androgen receptor antibody that has cross reactivity with
human and mouse receptors and rabbit antihuman PSA
antibody were used. Briefly, separate tumor sections were
blocked with 10% goat serum and then incubated with either
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rabbit antiandrogen receptor antibody (PG-21; Upstate, Lake
Placid, NY) (5 mg/ml) or rabbit anti-PSA antibody (Abcam,
Cambridge, MA) for 60 minutes at room temperature. After
washing thoroughly with PBS, the slides were incubated with
Cy3–conjugated goat antirabbit IgG at a 1:100 dilution
(Jackson ImmunoResearch, West Grove, PA) for 30 minutes
at room temperature, and then the sections were rinsed
again in PBS. The visualization of nuclei was developed with
4V,6-diamidino-2-phenylindole (DAPI; Sigma Chemical) for
5 minutes at room temperature. Slides were mounted with
a ProLong Antifade Kit (Molecular Probes, Eugene, OR) and
cover slips.
As a measure of apoptosis, the tumor sections were as-
sessed for DNA fragmentation by TUNEL assay performed
according to the manufacturer’s instructions (ApopTag Plus
FITC; Chemicon, Temecula, CA). For HONDA tumors, PSA
staining was performed following the TUNEL staining, and
nuclei were visualized by counterstaining with DAPI as
described above with the following changes: After TUNEL
staining, tissue sections were refixed with 4% paraformal-
dehyde for 10 minutes and washed in PBS. In sections
where MVD was assessed, the sections were first stained
with an antimouse CD31 antibody (monoclonal, MEC13.3;
BD PharMingen, San Diego, CA) and visualized with either
Cy2-Goat Antimouse IgG or Cy3 Goat Antimouse IgG
staining (Jackson ImmunoResearch) at a 1:100 dilution, and
then stained for PSA or androgen receptor as described
above. PSA positivity was used to assess the number of
cancer cells; CD31, a specific marker for mouse endothelial
cells, was used to assess the number of endothelial cells;
and DAPI positivity was used to assess the total number
of cells viewed.
Fluorescence microscopy was performed using an in-
verted microscope (Zeiss Axiovert 100 TV, Wetzlar, Ger-
many) fitted with appropriate filter sets (Omega Optical,
Brattleboro, VT). Images were acquired using a Photomet-
rics CH250 CCD (Photometrics, Tucson, AZ), with image ac-
quisition, pseudo-color image fusion, and storage controlled
by IP LabSpectrum software (Signal Analytics, Vienna, VA).
Quantification of Apoptosis and MVD and
Statistical Analysis
To quantify the degree of apoptosis, the total number of
TUNEL-positive (apoptotic) cells and PSA-positive (tumor)
cells were reported per 1000 PSA-positive (tumor) cells
counted at 400 magnification. The apoptotic index was
expressed as the ratio of TUNEL-positive tumor cells to all
tumor cells. MVD was also evaluated under 400 magnifi-
cation using CD31-stained sections as described earlier
[20]. The mean and standard deviation (SD) were obtained,
and unpaired Student’s t tests were performed to compare
between groups. A P value smaller than .05 was considered
to be statistically significant.
Results
Effect of 2-ME on Hormone-Dependent Prostate Cancer
The first step in our studies was to verify that HONDA
tumors grown in nude mice continued to express PSA and
androgen receptor. For these studies, tumors were grown
in vivo, excised, and stained for the expression of each pro-
tein. The HONDA tumors expressed intense signals for both
PSA and androgen receptor (Figure 2).
Figure 1. Experimental design: tumor apoptosis and MVD changes induced by 2-ME and androgen deprivation. HONDA xenograft and PC-3 human prostate
cancer models were used for TUNEL and CD31 immunohistochemical analysis. Twenty mice with HONDA tumor were sorted into four groups, each having the
same average tumor size. Mice bearing HONDA tumors were implanted with testosterone pellets 2 days prior to tumor implantation to promote tumor growth. To
control for the effects of surgical castration and pellet removal, animals in groups 1 and 2 underwent sham operations (SO). For PC-3 tumors, 10 mice were sorted
and assigned to groups 1 and 2 only. Testosterone pellets were not implanted prior to tumor implantation. All mice were then treated as indicated and, 72 hours
later, tumors were excised and evaluated histologically for apoptosis and MVD.
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We next determined the best time point to assess the ef-
ficacy of combining 2-ME and hormone deprivation therapy.
One, 3, or 7 days after initial treatment, animals harboring
HONDA tumors were euthanized and the tumors were re-
sected for histologic analysis. TUNEL assays indicated that
combination therapy resulted in a rapid increase in tumor
apoptosis (11.6-fold) within 24 hours, and that this increase
remained relatively unchanged for the 7-day observation
period (mean tumor sizes for control animals were 139 mm3
on day 0, 193 mm3 on day 1, 301 mm3 on day 3, 453 mm3 on
day 7, and 131, 139, 134, and 143 mm3 for the same time
points in the treated animals). In light of these results and
to avoid tumor reaction against hypoxia or reestablishment
of angiogenesis, which might be accelerated 3 days after
castration, as reported for the normal prostate gland [21–23],
we performed further studies at the 3-day time point.
To investigate in detail the effect of 2-ME on the andro-
gen-dependent HONDA tumors, animals were implanted
with tumors and sorted into four groups to compare the ef-
fects of the therapies administered independently or in com-
bination (Figure 1).
In animals that were treated with either 2-ME or andro-
gen deprivation therapy alone, tumor growth was slowed
but tumors did not regress. In contrast, combination of both
treatments resulted in tumor regression within the 3-day ob-
servation period (Figure 3). The changes in apoptosis paral-
leled those for tumor growth (Figure 4). Tumor sections from
mice treated with 2-ME had a 3.1-fold increased apoptotic
index comparedwith tumor sections from control mice. Those
that underwent androgen deprivation therapy showed an in-
crease apoptotic index of 5.3-fold compared with control.
The largest change, a 10.1-fold increase in apoptotic index,
was observed in tumors of mice treated with a combination
of 2-ME and androgen deprivation therapy. This degree of
apoptosis was also significantly elevated when compared
to that achieved with either agent alone (P = .0001 for 2-ME
and P = .018 for androgen deprivation). These data sug-
gest that there is a correlation between the degree of apop-
tosis and the extent to which HONDA tumors stop growing
and/or shrink.
Antiangiogenic Effect of 2-ME on Hormone-Dependent
Prostate Cancer
To determine the effects of treatment on tumor micro-
vasculature, the HONDA tumors were excised, sectioned,
and stained with anti-CD31 antibody (Figure 5). In these
studies, 2-ME treatment alone resulted in a 53.3% decrease
in MVD compared to tumors from control animals. Hormone
deprivation therapy alone resulted in less pronounced de-
creases in the MVD (31.3%). Simultaneous treatment of
the animals with both therapies was not significantly better
than either regimen alone, reducing the MVD by only 54.8%.
Therefore, the combination therapy with 2-ME and andro-
gen deprivation did not show an obvious advantage for
modulating MVD in this hormone-dependent cancer.
Figure 2. Immunohistochemical detection of androgen receptor and PSA in HONDA tumors. (a) The pseudo-color fluorescence images of androgen receptor and
CD31 double staining. The fusion images were obtained by overlaying three pseudo-color images. Blue indicates nuclei stained by DAPI; red color indicates Cy3-
labeled androgen receptor–positive cells; green color indicates Cy2-labeled CD31-positive cells. Note that the androgen receptor –positive cells show a pink color
as a result of overlaying red and blue colors. Please note that the endothelial cells (green-colored) did not stain with antiandrogen receptor antibody, which has
cross reactivity for both human and mouse androgen receptors. CD31 is a specific marker for mouse endothelial cells. (b) The pseudo-color fluorescence images of
PSA staining. The fusion images were obtained by overlaying two pseudo-color images. Blue color indicates nuclei stained by DAPI; red color indicates Cy3-
labeled PSA-positive cells. PSA is a marker for HONDA tumor cells.
Figure 3. Relative changes of HONDA tumor volume 72 hours after treat-
ment. Animals were treated as indicated and the tumor volumes were
measured before and after treatment. Each bar shows the percentage of
treated tumor volume in comparison with initial tumor volume. Error bars: ±
SD. Compared to control animals, the regression rates observed for 2-ME,
androgen ablation, and combination therapies were significant (P = .04, P =
.0027, and P = .0014, respectively). There were no significant differences
among the efficacies of 2-ME, androgen ablation, or combination therapies.
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It is important to note that, in several sections of tumors
isolated from treated animals, it was apparent that endo-
thelial cells also underwent apoptosis. As seen in Figure 6,
when tumor sections from animals treated with combination
therapy were stained for CD31 (an endothelial cell marker)
and with TUNEL, there were CD31-positive cells that were
also positive for apoptosis. Studies of tumors derived from
control animals did not show any cells staining for both
apoptosis and CD31 (data not shown).
Effect of 2-ME on Hormone-Independent Prostate Cancer
We also examined the 2-ME effect on hormone-
independent PC-3 prostate cancer using this in vivo model
system. Treatment of the animals harboring PC-3 tumors
with 2-ME showed a 2.43-fold increase in apoptosis com-
pared with the tumors from control animals with no observed
shrinkage in tumor volume (Figure 7). In contrast to these
modest changes in apoptosis, treatment with 2-ME resulted
in a 73% decrease in MVD compared to tumors growing in
control animals (Figure 8).
Discussion
In this study, we focused on the early in vivo effects of 2-ME
treatment on hormone-dependent (HONDA) and hormone-
independent (PC-3) prostate tumor models. Interestingly,
treatment of either tumor type in vivo with 2-ME alone had
very similar effects on the apoptotic index, increasing it be-
tween two-fold and three-fold. There was, however, a much
more pronounced decrease in MVD in hormone-independent
tumors. Combination therapy was most effective in treating
hormone-dependent cancers, significantly increasing the
apoptotic index over 10-fold and causing a shrinkage of
tumors within 3 days. The studies reported here are a pre-
requisite first step to begin to understand the mechanism
of—and determine if early combination therapy might be
more effective than—hormone deprivation therapy alone.
Although long-term relapse studies will be necessary to
determine the effectiveness of this approach for prostate
cancer patients, the results from these studies do support
further investigations of a therapeutic strategy that com-
bines hormone deprivation and chemotherapy with 2-ME.
Our studies demonstrate that 2-ME treatment results in an
increase in the number of TUNEL-positive cells in HONDA
and PC-3 tumors. Bu et al. [8] have reported using another
prostate tumor model, Dunning R3327-PAP, and a 14-day
administration of 2-ME, a good correlation between tumor
shrinkage and an increase in TUNEL-positive cells for tu-
mors treated in vivo. There are several possible mecha-
nisms by which 2-ME can induce apoptosis; however, it
seems clear from the work of Bu et al. [8] that 2-ME is not
an agonist for the estrogen receptors, suggesting that the
Figure 4. TUNEL staining and apoptotic index of HONDA tumors 72 hours after treatment. Animals were treated as described in Figure 1; tumors were resected
and analysed for PSA expression and apoptosis. (a) The fusion images were obtained by overlaying three pseudo-color images. Blue indicates nuclei stained
by DAPI; red indicates Cy3-labeled PSA-positive cells; green color indicates FITC-labeled TUNEL-positive cells. (b) Each bar shows the percentage of TUNEL-
positive (apoptotic) cells in 1000 PSA-positive (tumor) cells. Error bars: ± SD. AD, androgen deprivation. Compared to control animals, the apoptotic indices
observed for 2-ME, androgen ablation, and combination therapies were significant (P < .01, P < .01, and P < .01, respectively). The differences were also
significant when several of the treatments were compared: 2-ME versus combination therapy (P < .01); androgen ablation versus combination therapy (P < .05).
There was no significant difference between androgen ablation and 2-ME treatments (P = .7).
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Figure 5. Relative changes in MVD in HONDA tumors 72 hours after treatment. Animals harboring HONDA tumors were treated as described in Figure 1 and then
stained for PSA and CD31, a marker for mouse endothelial cells. (a) The fusion images were obtained by overlaying three pseudo-color images. Blue color
indicates nuclei stained by DAPI; red color indicates Cy3-labeled PSA-positive cells; green color indicates Cy2-labeled CD31-positive vasculature. (b) Each bar
shows the percentage of MVD in treated tumors in comparison with that in the control tumor. Error bars: ± SD. AD, androgen deprivation. Compared to control
animals, only treatments with 2-ME alone or 2-ME and androgen deprivation resulted in significant reductions in MVD (P < .01 for both). Androgen depletion did
not significantly reduce MVD. Similarly, the differences measured between different treatments were not statistically significant (AD vs 2-ME; AD vs 2-ME + AD;
and 2-ME vs 2-ME + AD).
Figure 6. Endothelial cells undergo apoptosis after combination therapy. Blue color indicates nuclei stained by DAPI; red color indicates Cy3-labeled CD31-positive
(endothelial) cells; green color indicates FITC-labeled TUNEL-positive (apoptosis) cells. The merged image was obtained by overlaying these three pseudo-colors.
Arrowheads indicate the cells that showed colocalization with CD31 and TUNEL-positive signals. CD31 is a marker for endothelial cells.
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antiproliferative activity of 2-ME must occur through another
pathway. One possible explanation for the antiproliferative ef-
fects of 2-ME is that it acts to induce apoptosis through the
JNK-dependent mitochondrial pathway [8,10,12,13], and
possibly by targeting p53 [13,24], the death receptor 5 [25],
and microtubles [9].
Figure 7. Changes in tumor volume and apoptotic rate for PC-3 tumors 72 hours after treatment. Animals harboring PC-3 tumors were treated as described
in Figure 1. (a) The tumor size was measured using microcalipers and tumor volume calculated as described in Materials and Methods section. Error bars: ± SD.
(b) The fusion images were obtained by overlaying two pseudo-color images. Blue indicates nuclei stained by DAPI; green color indicates FITC-labeled TUNEL-
positive cells. (c) Animals were treated with control or 2-ME, and the percentage of TUNEL-positive cells per 1000 tumor cells was determine. Error bars: ± SD. PC-3
cells were identified morphologically because they do not express PSA.
Figure 8. Relative changes of MVD in PC-3 tumors 72 hours after treatment. Animals were treated as outlined in Figure 1 and the changes in MVD were measured
by staining for CD31, an endothelial cell marker. (a) The fusion images were obtained by overlaying two pseudo-color images. Blue color indicates nuclei stained
by DAPI; green color indicates Cy2-labeled CD31-positive endothelial cells. (b) MVD was normalized to control tumors and expressed as a percentage for the
treated tumor. Error bars: ± SD. P = .0041.
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We were also able to demonstrate that 2-ME treat-
ment has antiangiogenic activities and decreases MVD
following in vivo treatment of either tumor type with 2-ME
(Figures 5 and 8). The decrease in MVD was greater,
however, for hormone-independent tumors. It is evident
that angiogenesis plays an important role in the growth
and spread of prostate cancer [26,27], and there are sev-
eral reports demonstrating the antiangiogenesis action
of 2-ME [3,9,10]. Mabjeesh et al. [9] have demonstrated
that 2-ME inhibits the expression of hypoxia-inducible
factor-1a (HIF-1a) and HIF-2a in PC-3 prostate cancer cells
as well as in MDA-MB-231 breast cancer cells. These de-
clines are associated with inhibition of the transcriptional
activation of vascular endothelial growth factor (VEGF) and
point to a potential mechanism for the antiangiogenic ac-
tion of 2-ME.
Angiogenesis inhibitors have been tested in clinical trials
[26], and, although some efficacy has been demonstrated,
there is now a much greater understanding of the diffi-
culties in assessing the efficacy and appropriate clinical
application of antiangiogenic agents [28,29]. Some reports
suggest that to achieve the maximal clinical benefit from
antiangiogenic agents, there may be a need to combine
these agents with other antiangiogenic or standard cytotoxic
agents [26,28]. One of the most important findings of our
study is that the combined therapy of 2-ME and androgen
deprivation caused a prominent increase in apoptosis and
significant decreases in tumor size for hormone-dependent
tumors compared to controls. However, when we measured
the effect of androgen deprivation alone, treatment with
2-ME alone, or combination therapy on MVD, we found very
similar decreases in MVD. Because the mechanisms for
antiangiogenesis caused by 2-ME and hormone depriva-
tion apparently both involve the suppression of VEGF ex-
pression, it is possible that VEGF can be maximally reduced
by either agent and combination therapy does not alter its
levels further. Therefore, under androgen deprivation status,
2-ME may act as an antiproliferative agent, not through
its antiangiogenic action but rather by its direct antitumor
action. The 2-ME antitumor (apoptosis) effect, combined
with hormone deprivation– induced effects on tumor cell
apoptosis and MVD, could result in the observed large in-
crease in tumor apoptosis and shrinkage. The effect of hor-
mone ablation in increasing pigment epithelium–derived
factor (PEDF) [21], an inhibitor of vascularization, may also
significantly contribute to the increase in tumor killing seen
and suggests that the effect of 2-ME on PEDF levels should
be investigated.
Clinically, androgen deprivation therapy, in combination
with surgical treatment, has been expected to increase the
survival of patients with localized prostate cancer that still
maintains hormone responsiveness. However, it is also
apparent that the effectiveness of hormone deprivation as
a single modality for preoperative treatment is insufficient,
and that neoadjuvant androgen deprivation therapy may
not contribute to improvement of patient survival rate [7].
The studies here show a significant increase in anticancer
effects against ADPC, compared to untreated control ani-
mals, when 2-ME and hormone deprivation therapy are
combined. Furthermore, although not statistically significant,
there is a trend for increased efficacy when the two agents
are used together rather than separately (Figure 3). Sup-
porting this trend is a statistically significant increase in the
ability of the combination treatment to induce apoptosis,
but not MVD, compared to androgen depletion or 2-ME treat-
ment alone. Recently, many investigators have suggested
that cytotoxic antitumor drugs induce apoptosis in vivo and,
like in vitro drug-induced apoptosis, this can be a relatively
rapid event [30–34]. Moreover, it has been shown that
apoptosis is a good early predictor of in vivo tumor response
to therapy [31,34]. Serial biopsies in breast cancer patients
have suggested that response to complete therapy corre-
lates with early posttreatment increases in the tumor’s apop-
totic index [32]. Mohsin et al. [34] reported that neoadjuvant
transtumab treatment for breast cancer patients significantly
induced apoptosis within 1 week and correlated with clinical
tumor regressions. Mohammed et al. [35] reported that there
was a strong association between doubling of the apoptotic
index and reduction in urinary bladder tumors. However, no
association or correlation was found between initial prolifer-
ative index or change in proliferation with treatment and
tumor response to therapeutic drug [33–35]. These data
demonstrate the importance of conducting further investi-
gations in which long-term studies will determine if combi-
nation therapy can be more effective at reducing tumor
burden than either of its components alone.
Even under androgen deprivation therapy, 2-ME exerts
strong direct killing effects on ADPC cells, suggesting that
the combination of 2-ME and androgen deprivation therapy
may be a reasonable strategy against ADPC. Potentially,
ADPC may not be completely androgen-dependent by na-
ture, and hormone ablation therapy may select for popula-
tions of cells containing pre-existing mutations that allow
AIPC to emerge. The combination of 2-ME treatment and
hormone deprivation therapy could potentially reduce this
population of cells and extend the period of regression that
most patients enjoy after hormone ablation therapy. This
particular combined therapy may potentially also achieve
clinically significant results, in combination with surgical treat-
ment or radiation therapy.
The results reported here may be useful in designing
future long-term animal relapse studies and eventually clini-
cal trials for prostate cancer. First, the 2-ME treatment may
be a promising therapy for AIPC. It is well known that AIPC
resists existing chemotherapeutic agents. Here we have
demonstrated that AIPC cells show significant sensitivity to
2-ME in vivo. Therefore, 2-ME may be a candidate thera-
peutic agent for patients with advanced AIPC. Second, the
combination therapy of 2-ME and androgen deprivation has
potential benefit for patients with ADPC. We feel that the
results described here should compel: 1) further examina-
tion of 2-ME and hormone deprivation therapy in longer-term
animal survival and relapse studies, and 2) eventually, the
combined results of these short-term and future long-term
studies may be used to inform the design of future clinical
trials for ADPC.
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